| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain, Postoperative | 42 | 2021 | 174 | 10.090 |
Why?
|
| Pain | 52 | 2017 | 282 | 10.060 |
Why?
|
| Anesthesiology | 23 | 2020 | 49 | 8.230 |
Why?
|
| Spinal Cord | 43 | 2018 | 139 | 7.900 |
Why?
|
| Analgesics | 36 | 2022 | 126 | 6.900 |
Why?
|
| Rats, Sprague-Dawley | 107 | 2020 | 747 | 6.030 |
Why?
|
| Rats | 124 | 2020 | 1604 | 5.870 |
Why?
|
| Clonidine | 28 | 2016 | 60 | 5.860 |
Why?
|
| Pain Measurement | 50 | 2019 | 365 | 5.620 |
Why?
|
| Hyperalgesia | 30 | 2020 | 88 | 5.110 |
Why?
|
| Spinal Nerves | 34 | 2020 | 65 | 5.050 |
Why?
|
| Neuralgia | 17 | 2019 | 48 | 4.160 |
Why?
|
| Animals | 138 | 2022 | 7302 | 4.070 |
Why?
|
| Ganglia, Spinal | 17 | 2020 | 63 | 3.590 |
Why?
|
| Analgesics, Opioid | 23 | 2018 | 243 | 3.500 |
Why?
|
| Injections, Spinal | 49 | 2018 | 124 | 3.470 |
Why?
|
| gamma-Aminobutyric Acid | 16 | 2019 | 74 | 3.420 |
Why?
|
| Cesarean Section | 11 | 2019 | 82 | 3.390 |
Why?
|
| Cyclooxygenase Inhibitors | 15 | 2015 | 39 | 3.320 |
Why?
|
| Ketorolac | 16 | 2015 | 24 | 3.310 |
Why?
|
| Periodicals as Topic | 12 | 2016 | 95 | 3.240 |
Why?
|
| Recovery of Function | 7 | 2019 | 190 | 3.200 |
Why?
|
| Pain Threshold | 38 | 2020 | 95 | 3.140 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 13 | 2018 | 32 | 3.060 |
Why?
|
| Locus Coeruleus | 11 | 2018 | 16 | 2.990 |
Why?
|
| Norepinephrine | 14 | 2018 | 73 | 2.880 |
Why?
|
| Nociceptors | 13 | 2020 | 41 | 2.850 |
Why?
|
| Oxytocin | 7 | 2019 | 22 | 2.830 |
Why?
|
| Adenosine | 14 | 2015 | 42 | 2.720 |
Why?
|
| Cyclohexanecarboxylic Acids | 11 | 2016 | 20 | 2.620 |
Why?
|
| Amines | 11 | 2016 | 22 | 2.620 |
Why?
|
| Male | 127 | 2020 | 17872 | 2.620 |
Why?
|
| Adrenergic alpha-Agonists | 17 | 2007 | 41 | 2.620 |
Why?
|
| Morphine | 16 | 2010 | 57 | 2.540 |
Why?
|
| Analgesia | 9 | 2018 | 33 | 2.400 |
Why?
|
| Physical Stimulation | 30 | 2018 | 84 | 2.310 |
Why?
|
| Piperidines | 9 | 2016 | 125 | 2.260 |
Why?
|
| Mechanoreceptors | 12 | 2020 | 37 | 2.250 |
Why?
|
| Sciatic Nerve | 13 | 2006 | 35 | 2.200 |
Why?
|
| Bupivacaine | 8 | 2018 | 48 | 2.130 |
Why?
|
| Behavior, Animal | 23 | 2017 | 264 | 2.110 |
Why?
|
| Neurons, Afferent | 10 | 2017 | 54 | 2.010 |
Why?
|
| Sciatic Neuropathy | 9 | 2007 | 15 | 2.000 |
Why?
|
| Ligation | 28 | 2019 | 55 | 1.900 |
Why?
|
| Publishing | 6 | 2016 | 57 | 1.870 |
Why?
|
| Disease Models, Animal | 29 | 2019 | 981 | 1.760 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 9 | 2010 | 32 | 1.720 |
Why?
|
| Dose-Response Relationship, Drug | 30 | 2015 | 641 | 1.710 |
Why?
|
| Peripheral Nervous System Diseases | 9 | 2011 | 45 | 1.640 |
Why?
|
| Anesthetics, Local | 8 | 2021 | 77 | 1.640 |
Why?
|
| Hot Temperature | 12 | 2018 | 71 | 1.630 |
Why?
|
| Female | 66 | 2019 | 18236 | 1.630 |
Why?
|
| Capsaicin | 10 | 2018 | 30 | 1.620 |
Why?
|
| Humans | 76 | 2022 | 29213 | 1.550 |
Why?
|
| Cervix Uteri | 9 | 2008 | 21 | 1.540 |
Why?
|
| Pregnancy | 20 | 2019 | 816 | 1.520 |
Why?
|
| Postpartum Period | 6 | 2018 | 29 | 1.520 |
Why?
|
| Glutamic Acid | 8 | 2018 | 46 | 1.510 |
Why?
|
| Neural Inhibition | 4 | 2018 | 27 | 1.490 |
Why?
|
| Cholinesterase Inhibitors | 5 | 2013 | 29 | 1.400 |
Why?
|
| Science | 3 | 2016 | 8 | 1.370 |
Why?
|
| Analgesia, Obstetrical | 6 | 2017 | 47 | 1.290 |
Why?
|
| Touch | 6 | 2020 | 35 | 1.290 |
Why?
|
| Neuronal Plasticity | 5 | 2012 | 81 | 1.280 |
Why?
|
| Fentanyl | 6 | 2017 | 33 | 1.270 |
Why?
|
| Sensory Receptor Cells | 3 | 2019 | 29 | 1.250 |
Why?
|
| Biomedical Research | 4 | 2013 | 154 | 1.230 |
Why?
|
| Adult | 34 | 2019 | 8466 | 1.220 |
Why?
|
| Action Potentials | 8 | 2019 | 174 | 1.210 |
Why?
|
| Posterior Horn Cells | 7 | 2012 | 11 | 1.180 |
Why?
|
| Research Design | 5 | 2016 | 286 | 1.170 |
Why?
|
| Ketamine | 3 | 2017 | 20 | 1.150 |
Why?
|
| Time Factors | 24 | 2017 | 2003 | 1.150 |
Why?
|
| Isoenzymes | 5 | 2004 | 63 | 1.140 |
Why?
|
| Neostigmine | 4 | 2017 | 16 | 1.100 |
Why?
|
| Receptors, Oxytocin | 2 | 2018 | 8 | 1.080 |
Why?
|
| Uterus | 6 | 2004 | 73 | 1.070 |
Why?
|
| Photic Stimulation | 2 | 2017 | 155 | 1.070 |
Why?
|
| Neurons | 6 | 2018 | 394 | 1.000 |
Why?
|
| Cyclooxygenase 1 | 9 | 2006 | 23 | 1.000 |
Why?
|
| Parturition | 3 | 2014 | 9 | 0.990 |
Why?
|
| Peripheral Nerves | 8 | 2021 | 59 | 0.980 |
Why?
|
| Receptors, Nicotinic | 5 | 2009 | 60 | 0.960 |
Why?
|
| Oxytocics | 2 | 2014 | 11 | 0.930 |
Why?
|
| Lidocaine | 3 | 2014 | 17 | 0.930 |
Why?
|
| Attention | 4 | 2018 | 84 | 0.910 |
Why?
|
| Receptors, Purinergic P1 | 4 | 2004 | 7 | 0.900 |
Why?
|
| Nerve Block | 3 | 2021 | 48 | 0.890 |
Why?
|
| Research | 4 | 2020 | 72 | 0.870 |
Why?
|
| Reaction Time | 4 | 2018 | 121 | 0.860 |
Why?
|
| Receptor, Adenosine A1 | 4 | 2006 | 6 | 0.850 |
Why?
|
| Receptors, Vasopressin | 2 | 2019 | 7 | 0.840 |
Why?
|
| Ondansetron | 2 | 2012 | 5 | 0.820 |
Why?
|
| Inflammation | 6 | 2017 | 508 | 0.820 |
Why?
|
| Postoperative Complications | 4 | 2017 | 670 | 0.810 |
Why?
|
| Anesthesia, Epidural | 3 | 2009 | 23 | 0.810 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2015 | 16 | 0.790 |
Why?
|
| Indans | 4 | 2013 | 25 | 0.790 |
Why?
|
| Cues | 3 | 2017 | 67 | 0.790 |
Why?
|
| Double-Blind Method | 12 | 2017 | 504 | 0.780 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 2011 | 36 | 0.780 |
Why?
|
| Immunohistochemistry | 15 | 2012 | 519 | 0.760 |
Why?
|
| Delivery, Obstetric | 2 | 2013 | 50 | 0.750 |
Why?
|
| Receptors, Opioid, kappa | 5 | 2005 | 40 | 0.750 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2018 | 84 | 0.740 |
Why?
|
| Afferent Pathways | 4 | 2019 | 23 | 0.740 |
Why?
|
| Laparotomy | 5 | 2011 | 32 | 0.730 |
Why?
|
| Pyrazoles | 5 | 2006 | 65 | 0.720 |
Why?
|
| Synaptosomes | 8 | 2014 | 17 | 0.710 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 80 | 0.700 |
Why?
|
| Anesthesia, Obstetrical | 3 | 2013 | 22 | 0.690 |
Why?
|
| Labor Pain | 2 | 2009 | 8 | 0.690 |
Why?
|
| Signal Transduction | 4 | 2018 | 666 | 0.680 |
Why?
|
| Hindlimb | 5 | 2014 | 57 | 0.680 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 59 | 0.670 |
Why?
|
| Spinal Nerve Roots | 4 | 2007 | 14 | 0.670 |
Why?
|
| Exploratory Behavior | 3 | 2009 | 30 | 0.650 |
Why?
|
| TRPV Cation Channels | 6 | 2019 | 19 | 0.650 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 298 | 0.650 |
Why?
|
| Estrogens | 6 | 2007 | 162 | 0.650 |
Why?
|
| Choice Behavior | 2 | 2019 | 83 | 0.640 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2018 | 23 | 0.640 |
Why?
|
| Analgesia, Patient-Controlled | 3 | 2017 | 19 | 0.640 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 47 | 0.630 |
Why?
|
| Amino Acid Transport System X-AG | 4 | 2014 | 4 | 0.630 |
Why?
|
| Surgical Procedures, Operative | 2 | 2010 | 75 | 0.610 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 6 | 2018 | 7 | 0.610 |
Why?
|
| Thiophenes | 4 | 2008 | 21 | 0.610 |
Why?
|
| Abdominal Pain | 1 | 2017 | 40 | 0.610 |
Why?
|
| Acetylcholine | 5 | 2011 | 47 | 0.610 |
Why?
|
| Delirium | 1 | 2017 | 13 | 0.600 |
Why?
|
| Societies, Medical | 3 | 2020 | 149 | 0.600 |
Why?
|
| Pupil | 1 | 2017 | 2 | 0.600 |
Why?
|
| Predictive Value of Tests | 7 | 2018 | 788 | 0.590 |
Why?
|
| Rats, Inbred F344 | 7 | 2018 | 125 | 0.590 |
Why?
|
| Ion Channels | 3 | 2005 | 24 | 0.590 |
Why?
|
| Anesthetics, Intravenous | 2 | 2010 | 17 | 0.590 |
Why?
|
| Blood Pressure | 8 | 2014 | 807 | 0.580 |
Why?
|
| Editorial Policies | 3 | 2013 | 12 | 0.580 |
Why?
|
| Neural Conduction | 6 | 2017 | 81 | 0.580 |
Why?
|
| Art | 1 | 2016 | 1 | 0.570 |
Why?
|
| Psychomotor Performance | 2 | 2014 | 97 | 0.570 |
Why?
|
| Up-Regulation | 5 | 2011 | 183 | 0.570 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 240 | 0.570 |
Why?
|
| Analgesia, Epidural | 3 | 2017 | 50 | 0.570 |
Why?
|
| Anesthesia | 3 | 2020 | 65 | 0.560 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2004 | 71 | 0.560 |
Why?
|
| Respiration | 1 | 2016 | 26 | 0.550 |
Why?
|
| Young Adult | 10 | 2018 | 2413 | 0.540 |
Why?
|
| Sensory System Agents | 2 | 2014 | 7 | 0.540 |
Why?
|
| GTP-Binding Proteins | 3 | 2005 | 24 | 0.540 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 726 | 0.540 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 2 | 2012 | 3 | 0.540 |
Why?
|
| Receptors, Muscarinic | 2 | 2007 | 10 | 0.540 |
Why?
|
| Case-Control Studies | 2 | 2018 | 860 | 0.520 |
Why?
|
| Online Systems | 1 | 2015 | 13 | 0.520 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2015 | 19 | 0.510 |
Why?
|
| Labor, Obstetric | 4 | 2017 | 31 | 0.510 |
Why?
|
| Prostaglandins | 2 | 2006 | 17 | 0.500 |
Why?
|
| Hypersensitivity | 2 | 2013 | 25 | 0.500 |
Why?
|
| Exercise | 1 | 2019 | 595 | 0.490 |
Why?
|
| Anesthetics, Combined | 1 | 2014 | 5 | 0.490 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2014 | 5 | 0.490 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 5 | 2010 | 18 | 0.490 |
Why?
|
| Conditioning, Operant | 2 | 2005 | 96 | 0.490 |
Why?
|
| Calcium | 4 | 2011 | 297 | 0.490 |
Why?
|
| Astrocytes | 6 | 2015 | 49 | 0.490 |
Why?
|
| Lung Diseases | 1 | 2014 | 45 | 0.490 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2014 | 17 | 0.490 |
Why?
|
| Anesthesia, Spinal | 2 | 2014 | 21 | 0.480 |
Why?
|
| Fraud | 1 | 2013 | 1 | 0.480 |
Why?
|
| Nitric Oxide | 4 | 2018 | 116 | 0.480 |
Why?
|
| Bisoprolol | 1 | 2013 | 1 | 0.480 |
Why?
|
| Atenolol | 1 | 2013 | 6 | 0.480 |
Why?
|
| Metoprolol | 1 | 2013 | 3 | 0.480 |
Why?
|
| Aging | 3 | 2006 | 881 | 0.470 |
Why?
|
| Educational Measurement | 1 | 2014 | 111 | 0.470 |
Why?
|
| Off-Label Use | 2 | 2010 | 11 | 0.460 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 116 | 0.460 |
Why?
|
| Rats, Wistar | 7 | 2007 | 84 | 0.460 |
Why?
|
| Cyclooxygenase 2 | 4 | 2006 | 50 | 0.450 |
Why?
|
| Theobromine | 2 | 2003 | 2 | 0.450 |
Why?
|
| Adrenergic alpha-Antagonists | 7 | 2007 | 27 | 0.450 |
Why?
|
| Chronic Disease | 7 | 2010 | 370 | 0.440 |
Why?
|
| Nerve Fibers | 2 | 2014 | 30 | 0.430 |
Why?
|
| Skin | 5 | 2014 | 203 | 0.420 |
Why?
|
| Cognition | 1 | 2016 | 526 | 0.410 |
Why?
|
| Schools, Medical | 1 | 2011 | 42 | 0.410 |
Why?
|
| Treatment Outcome | 6 | 2017 | 3108 | 0.410 |
Why?
|
| Middle Aged | 14 | 2017 | 10868 | 0.410 |
Why?
|
| Drug Approval | 2 | 2010 | 9 | 0.400 |
Why?
|
| Academies and Institutes | 1 | 2010 | 5 | 0.390 |
Why?
|
| Sulfonamides | 3 | 2006 | 65 | 0.390 |
Why?
|
| Models, Animal | 2 | 2008 | 160 | 0.390 |
Why?
|
| Cholinergic Fibers | 1 | 2010 | 7 | 0.380 |
Why?
|
| Neuroglia | 4 | 2015 | 29 | 0.370 |
Why?
|
| Infusions, Intravenous | 5 | 2015 | 85 | 0.370 |
Why?
|
| Microglia | 2 | 2010 | 48 | 0.370 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 47 | 0.360 |
Why?
|
| Labor Stage, First | 1 | 2009 | 6 | 0.360 |
Why?
|
| Idazoxan | 4 | 2018 | 10 | 0.360 |
Why?
|
| Indoles | 5 | 2010 | 58 | 0.360 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 2114 | 0.350 |
Why?
|
| Lumbar Vertebrae | 4 | 2019 | 98 | 0.350 |
Why?
|
| Retraction of Publication as Topic | 1 | 2009 | 1 | 0.350 |
Why?
|
| Membrane Potentials | 5 | 2014 | 80 | 0.350 |
Why?
|
| Scientific Misconduct | 1 | 2009 | 4 | 0.350 |
Why?
|
| Electromyography | 7 | 2004 | 58 | 0.350 |
Why?
|
| Professional Role | 1 | 2009 | 19 | 0.340 |
Why?
|
| Spinal Cord Injuries | 2 | 2006 | 32 | 0.340 |
Why?
|
| Depression, Postpartum | 1 | 2008 | 9 | 0.330 |
Why?
|
| Gene Expression Regulation | 3 | 2011 | 481 | 0.330 |
Why?
|
| Prospective Studies | 4 | 2019 | 2027 | 0.330 |
Why?
|
| Dizocilpine Maleate | 1 | 2008 | 7 | 0.330 |
Why?
|
| Membrane Proteins | 6 | 2006 | 256 | 0.330 |
Why?
|
| N-Methylaspartate | 1 | 2008 | 12 | 0.330 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2019 | 8 | 0.330 |
Why?
|
| Pregnancy, Animal | 1 | 2008 | 19 | 0.330 |
Why?
|
| Anesthesia, Conduction | 1 | 2008 | 29 | 0.330 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2014 | 26 | 0.320 |
Why?
|
| Physicians | 1 | 2010 | 135 | 0.320 |
Why?
|
| Cells, Cultured | 6 | 2011 | 800 | 0.320 |
Why?
|
| Stroke | 1 | 2013 | 549 | 0.320 |
Why?
|
| Immunotoxins | 2 | 2011 | 16 | 0.320 |
Why?
|
| Bayes Theorem | 2 | 2018 | 68 | 0.320 |
Why?
|
| Dopamine beta-Hydroxylase | 4 | 2011 | 5 | 0.320 |
Why?
|
| Naloxone | 4 | 2016 | 23 | 0.310 |
Why?
|
| Drug Synergism | 6 | 2011 | 67 | 0.310 |
Why?
|
| Cytokines | 2 | 2006 | 243 | 0.310 |
Why?
|
| Mass Media | 1 | 2007 | 12 | 0.310 |
Why?
|
| Cyclopropanes | 2 | 2004 | 20 | 0.300 |
Why?
|
| Heart Rate | 6 | 2014 | 315 | 0.300 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2007 | 16 | 0.300 |
Why?
|
| Postoperative Period | 2 | 2018 | 91 | 0.300 |
Why?
|
| Analysis of Variance | 6 | 2016 | 454 | 0.300 |
Why?
|
| Atropine | 5 | 2016 | 16 | 0.290 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2006 | 17 | 0.290 |
Why?
|
| Receptors, Opioid, mu | 3 | 2012 | 51 | 0.290 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 36 | 0.290 |
Why?
|
| Dynorphins | 1 | 2006 | 9 | 0.290 |
Why?
|
| Stress, Psychological | 2 | 2018 | 210 | 0.290 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2006 | 8 | 0.280 |
Why?
|
| Somatostatin | 1 | 2006 | 10 | 0.280 |
Why?
|
| Health Status | 1 | 2008 | 369 | 0.280 |
Why?
|
| Narcotic Antagonists | 5 | 2016 | 51 | 0.280 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 69 | 0.280 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2006 | 41 | 0.280 |
Why?
|
| Cross-Over Studies | 3 | 2015 | 95 | 0.280 |
Why?
|
| Neuritis | 1 | 2005 | 4 | 0.270 |
Why?
|
| Visceral Afferents | 2 | 2003 | 2 | 0.270 |
Why?
|
| Risk Assessment | 2 | 2008 | 1312 | 0.270 |
Why?
|
| Electric Stimulation | 3 | 2019 | 102 | 0.270 |
Why?
|
| Meperidine | 1 | 2005 | 1 | 0.270 |
Why?
|
| Butorphanol | 1 | 2005 | 4 | 0.270 |
Why?
|
| Abdomen | 1 | 2005 | 42 | 0.260 |
Why?
|
| Adolescent | 6 | 2018 | 3265 | 0.260 |
Why?
|
| Choline O-Acetyltransferase | 3 | 2011 | 10 | 0.260 |
Why?
|
| Dogs | 3 | 2014 | 117 | 0.260 |
Why?
|
| Stress, Physiological | 1 | 2005 | 44 | 0.260 |
Why?
|
| Injections | 3 | 2018 | 61 | 0.260 |
Why?
|
| Morpholines | 1 | 2005 | 34 | 0.260 |
Why?
|
| Injections, Intravenous | 5 | 2005 | 73 | 0.250 |
Why?
|
| Pyrimidines | 1 | 2005 | 60 | 0.250 |
Why?
|
| Apoptosis | 1 | 2006 | 337 | 0.250 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 43 | 0.250 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 142 | 0.250 |
Why?
|
| Cystatins | 1 | 2004 | 8 | 0.240 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2003 | 4 | 0.240 |
Why?
|
| Regression Analysis | 3 | 2013 | 274 | 0.240 |
Why?
|
| Transcription Factors | 1 | 2005 | 172 | 0.240 |
Why?
|
| Postoperative Care | 1 | 2004 | 72 | 0.240 |
Why?
|
| Risk Factors | 5 | 2018 | 3547 | 0.240 |
Why?
|
| Dinoprostone | 1 | 2003 | 37 | 0.240 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 30 | 0.230 |
Why?
|
| Glial Fibrillary Acidic Protein | 4 | 2014 | 37 | 0.230 |
Why?
|
| Genes, fos | 1 | 2003 | 4 | 0.230 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 90 | 0.230 |
Why?
|
| Antidepressive Agents | 1 | 2004 | 70 | 0.230 |
Why?
|
| Choline | 1 | 2003 | 14 | 0.230 |
Why?
|
| Ovariectomy | 5 | 2004 | 147 | 0.230 |
Why?
|
| Receptors, Cholinergic | 1 | 2003 | 22 | 0.230 |
Why?
|
| Anesthetics, Dissociative | 1 | 2003 | 4 | 0.230 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 196 | 0.230 |
Why?
|
| Xanthines | 4 | 2004 | 7 | 0.230 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 73 | 0.230 |
Why?
|
| Prilocaine | 1 | 2002 | 1 | 0.220 |
Why?
|
| Drug Hypersensitivity | 1 | 2002 | 8 | 0.220 |
Why?
|
| Riluzole | 3 | 2011 | 5 | 0.220 |
Why?
|
| Imidazoles | 4 | 2015 | 104 | 0.220 |
Why?
|
| Pancreatitis | 1 | 2003 | 18 | 0.220 |
Why?
|
| Microdialysis | 5 | 2014 | 33 | 0.220 |
Why?
|
| GABA Antagonists | 3 | 2018 | 12 | 0.220 |
Why?
|
| S-Nitrosothiols | 1 | 2002 | 5 | 0.220 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 7 | 0.220 |
Why?
|
| Valproic Acid | 2 | 2013 | 14 | 0.220 |
Why?
|
| Random Allocation | 3 | 2014 | 213 | 0.220 |
Why?
|
| Vasotocin | 2 | 2013 | 2 | 0.220 |
Why?
|
| Hormone Antagonists | 2 | 2013 | 3 | 0.220 |
Why?
|
| Cohort Studies | 3 | 2017 | 1694 | 0.220 |
Why?
|
| Naltrexone | 1 | 2002 | 38 | 0.220 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2002 | 5 | 0.220 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 4 | 2007 | 24 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 466 | 0.210 |
Why?
|
| Serotonin Antagonists | 2 | 2012 | 5 | 0.210 |
Why?
|
| Drug Combinations | 3 | 2007 | 86 | 0.200 |
Why?
|
| Administration, Oral | 3 | 2007 | 169 | 0.200 |
Why?
|
| Phosphorylation | 3 | 2010 | 225 | 0.200 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 118 | 0.200 |
Why?
|
| Cysteine | 1 | 2002 | 131 | 0.200 |
Why?
|
| Catheterization | 5 | 2006 | 58 | 0.200 |
Why?
|
| Phantom Limb | 1 | 2021 | 4 | 0.200 |
Why?
|
| Isoindoles | 3 | 2006 | 6 | 0.200 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 8 | 0.200 |
Why?
|
| History, 20th Century | 2 | 2013 | 68 | 0.190 |
Why?
|
| Peer Review | 2 | 2011 | 6 | 0.190 |
Why?
|
| Perioperative Care | 2 | 2012 | 58 | 0.190 |
Why?
|
| Age Factors | 4 | 2012 | 1110 | 0.190 |
Why?
|
| Functional Laterality | 3 | 2011 | 59 | 0.190 |
Why?
|
| Allosteric Regulation | 3 | 2005 | 11 | 0.180 |
Why?
|
| Cold Temperature | 2 | 2017 | 39 | 0.180 |
Why?
|
| Muscarinic Antagonists | 3 | 2005 | 15 | 0.180 |
Why?
|
| Calcium-Binding Proteins | 2 | 2011 | 45 | 0.180 |
Why?
|
| Microfilament Proteins | 2 | 2011 | 33 | 0.180 |
Why?
|
| Tachykinins | 1 | 2019 | 3 | 0.170 |
Why?
|
| Preoperative Care | 2 | 2013 | 110 | 0.170 |
Why?
|
| Comorbidity | 2 | 2013 | 546 | 0.170 |
Why?
|
| Hemodynamics | 3 | 2004 | 148 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2019 | 267 | 0.170 |
Why?
|
| Culture | 1 | 2018 | 38 | 0.160 |
Why?
|
| Macrophages | 3 | 2006 | 188 | 0.160 |
Why?
|
| Breath Tests | 1 | 2018 | 18 | 0.160 |
Why?
|
| Swine | 1 | 2018 | 201 | 0.160 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 17 | 0.160 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2010 | 9 | 0.160 |
Why?
|
| Linear Models | 2 | 2013 | 427 | 0.160 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 2 | 2011 | 6 | 0.160 |
Why?
|
| Inpatients | 1 | 2018 | 64 | 0.160 |
Why?
|
| Brain | 1 | 2005 | 930 | 0.160 |
Why?
|
| Heart Rate, Fetal | 2 | 2009 | 7 | 0.150 |
Why?
|
| Injections, Epidural | 2 | 2010 | 9 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 53 | 0.150 |
Why?
|
| Incidence | 2 | 2013 | 1123 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 864 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2018 | 169 | 0.150 |
Why?
|
| Eye Movement Measurements | 1 | 2017 | 4 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2018 | 478 | 0.150 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2014 | 31 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 246 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2008 | 80 | 0.150 |
Why?
|
| Artifacts | 1 | 2017 | 38 | 0.150 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 2 | 2008 | 4 | 0.150 |
Why?
|
| Thoracic Vertebrae | 1 | 2017 | 42 | 0.140 |
Why?
|
| Amides | 1 | 2016 | 20 | 0.140 |
Why?
|
| Electrophysiological Phenomena | 2 | 2019 | 28 | 0.140 |
Why?
|
| Zymosan | 2 | 2007 | 5 | 0.140 |
Why?
|
| Amitriptyline | 2 | 2008 | 7 | 0.140 |
Why?
|
| Anesthetics | 1 | 2016 | 19 | 0.140 |
Why?
|
| Neural Pathways | 2 | 2010 | 97 | 0.140 |
Why?
|
| Organ Size | 1 | 2017 | 196 | 0.140 |
Why?
|
| Leukocytes | 2 | 2006 | 52 | 0.140 |
Why?
|
| Meditation | 1 | 2016 | 22 | 0.140 |
Why?
|
| Skin Temperature | 1 | 2015 | 15 | 0.140 |
Why?
|
| Hematologic Tests | 1 | 2015 | 11 | 0.140 |
Why?
|
| Cell Count | 2 | 2006 | 50 | 0.140 |
Why?
|
| Drug Tolerance | 2 | 2007 | 36 | 0.140 |
Why?
|
| Sodium Chloride | 2 | 2008 | 24 | 0.130 |
Why?
|
| Acute Disease | 2 | 2008 | 239 | 0.130 |
Why?
|
| Pyramidal Tracts | 1 | 2015 | 3 | 0.130 |
Why?
|
| Self Administration | 2 | 2007 | 296 | 0.130 |
Why?
|
| Prevalence | 1 | 2018 | 907 | 0.130 |
Why?
|
| Neurotoxins | 2 | 2006 | 16 | 0.130 |
Why?
|
| Receptor, Muscarinic M4 | 2 | 2006 | 6 | 0.130 |
Why?
|
| Stimulation, Chemical | 1 | 2015 | 12 | 0.130 |
Why?
|
| Anxiety, Separation | 1 | 2014 | 1 | 0.130 |
Why?
|
| Leukocyte Count | 2 | 2005 | 55 | 0.130 |
Why?
|
| Back Pain | 2 | 2007 | 28 | 0.130 |
Why?
|
| Muscle Spindles | 1 | 2014 | 4 | 0.130 |
Why?
|
| Stereotyped Behavior | 2 | 2005 | 14 | 0.130 |
Why?
|
| Nitrobenzenes | 2 | 2006 | 10 | 0.130 |
Why?
|
| Fura-2 | 2 | 2005 | 4 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2015 | 159 | 0.120 |
Why?
|
| Toxicity Tests, Chronic | 1 | 2014 | 3 | 0.120 |
Why?
|
| Sex Characteristics | 1 | 2014 | 167 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2014 | 211 | 0.120 |
Why?
|
| Pruritus | 1 | 2014 | 58 | 0.120 |
Why?
|
| Sensory Thresholds | 3 | 2011 | 26 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2014 | 48 | 0.120 |
Why?
|
| Internationality | 2 | 2010 | 21 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2013 | 17 | 0.110 |
Why?
|
| Weaning | 1 | 2013 | 6 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2013 | 48 | 0.110 |
Why?
|
| Cholinergic Agents | 1 | 2013 | 6 | 0.110 |
Why?
|
| Dilatation | 2 | 2003 | 9 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2018 | 3121 | 0.110 |
Why?
|
| Food | 2 | 2019 | 41 | 0.110 |
Why?
|
| Acoustic Stimulation | 1 | 2013 | 125 | 0.110 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 2 | 2002 | 13 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2013 | 74 | 0.110 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2002 | 15 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2013 | 164 | 0.110 |
Why?
|
| Anterior Horn Cells | 1 | 2011 | 2 | 0.110 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2011 | 5 | 0.110 |
Why?
|
| Motor Activity | 2 | 2005 | 311 | 0.110 |
Why?
|
| Tritium | 1 | 2011 | 17 | 0.110 |
Why?
|
| Missouri | 1 | 2011 | 12 | 0.110 |
Why?
|
| Opioid Peptides | 1 | 2012 | 28 | 0.100 |
Why?
|
| Microscopy, Video | 1 | 2011 | 7 | 0.100 |
Why?
|
| Body Weight | 2 | 2004 | 290 | 0.100 |
Why?
|
| Corticosterone | 1 | 2011 | 9 | 0.100 |
Why?
|
| Anxiety | 1 | 2013 | 159 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 81 | 0.100 |
Why?
|
| Excitatory Amino Acid Transporter 1 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2011 | 13 | 0.100 |
Why?
|
| Headache | 1 | 2012 | 74 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2015 | 283 | 0.100 |
Why?
|
| Fever | 1 | 2011 | 56 | 0.100 |
Why?
|
| Indole Alkaloids | 1 | 2011 | 1 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 107 | 0.100 |
Why?
|
| Carbazoles | 1 | 2011 | 6 | 0.100 |
Why?
|
| Sweden | 1 | 2010 | 14 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 129 | 0.100 |
Why?
|
| Quinolizines | 1 | 2010 | 2 | 0.100 |
Why?
|
| Japan | 1 | 2010 | 15 | 0.090 |
Why?
|
| Tibial Nerve | 1 | 2010 | 16 | 0.090 |
Why?
|
| Central Nervous System Agents | 1 | 2010 | 3 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2010 | 46 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 162 | 0.090 |
Why?
|
| Informed Consent | 1 | 2010 | 51 | 0.090 |
Why?
|
| Solubility | 1 | 2009 | 38 | 0.090 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2009 | 1 | 0.090 |
Why?
|
| Thinking | 1 | 2009 | 6 | 0.090 |
Why?
|
| Conscious Sedation | 1 | 2009 | 24 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 375 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 52 | 0.080 |
Why?
|
| Nicotinic Agonists | 1 | 2009 | 49 | 0.080 |
Why?
|
| New York | 1 | 2008 | 18 | 0.080 |
Why?
|
| Heart | 1 | 2010 | 162 | 0.080 |
Why?
|
| Awards and Prizes | 1 | 2008 | 11 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 711 | 0.080 |
Why?
|
| Nootropic Agents | 1 | 2008 | 13 | 0.080 |
Why?
|
| Nesting Behavior | 1 | 2008 | 3 | 0.080 |
Why?
|
| Hypogastric Plexus | 1 | 2008 | 5 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 105 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2009 | 126 | 0.080 |
Why?
|
| Diffusion of Innovation | 1 | 2008 | 29 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2008 | 37 | 0.080 |
Why?
|
| Sulfamethizole | 1 | 2008 | 1 | 0.080 |
Why?
|
| Memantine | 1 | 2008 | 4 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 200 | 0.080 |
Why?
|
| Electrophysiology | 1 | 2008 | 66 | 0.080 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2008 | 7 | 0.080 |
Why?
|
| Protein Binding | 2 | 2006 | 199 | 0.080 |
Why?
|
| Infusions, Parenteral | 1 | 2008 | 64 | 0.080 |
Why?
|
| Lipids | 1 | 2009 | 211 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 638 | 0.080 |
Why?
|
| Aged | 3 | 2017 | 9510 | 0.080 |
Why?
|
| Carrageenan | 2 | 2009 | 5 | 0.080 |
Why?
|
| American Heart Association | 1 | 2008 | 84 | 0.080 |
Why?
|
| Dilatation, Pathologic | 1 | 2007 | 19 | 0.080 |
Why?
|
| Cyclohexanes | 1 | 2007 | 4 | 0.080 |
Why?
|
| Critical Care | 1 | 2008 | 114 | 0.080 |
Why?
|
| Bee Venoms | 1 | 2007 | 1 | 0.080 |
Why?
|
| Reflex | 1 | 2007 | 15 | 0.080 |
Why?
|
| Hydromorphone | 1 | 2007 | 4 | 0.080 |
Why?
|
| Cyclohexanols | 1 | 2007 | 20 | 0.080 |
Why?
|
| Phenols | 1 | 2007 | 16 | 0.080 |
Why?
|
| Methadone | 1 | 2007 | 12 | 0.070 |
Why?
|
| Heroin | 1 | 2007 | 14 | 0.070 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2006 | 4 | 0.070 |
Why?
|
| Anesthesia, Local | 1 | 2006 | 16 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2006 | 30 | 0.070 |
Why?
|
| Pressure | 2 | 2004 | 54 | 0.070 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 12 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 27 | 0.070 |
Why?
|
| Postural Balance | 1 | 2008 | 160 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2006 | 126 | 0.070 |
Why?
|
| Administration, Cutaneous | 1 | 2006 | 107 | 0.070 |
Why?
|
| Internet | 1 | 2007 | 158 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 70 | 0.070 |
Why?
|
| Axotomy | 1 | 2005 | 2 | 0.070 |
Why?
|
| Ileus | 1 | 2005 | 5 | 0.070 |
Why?
|
| Abdominal Muscles | 1 | 2005 | 6 | 0.070 |
Why?
|
| Cell Movement | 1 | 2006 | 161 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 172 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2006 | 111 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 109 | 0.070 |
Why?
|
| Antibody Formation | 1 | 2005 | 39 | 0.070 |
Why?
|
| Spinal Fusion | 1 | 2006 | 42 | 0.070 |
Why?
|
| Nerve Endings | 1 | 2005 | 4 | 0.070 |
Why?
|
| Uterine Contraction | 1 | 2005 | 7 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 2005 | 43 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2005 | 3 | 0.070 |
Why?
|
| Cell Size | 1 | 2005 | 32 | 0.060 |
Why?
|
| United States | 3 | 2008 | 3648 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2004 | 48 | 0.060 |
Why?
|
| Sucrose | 1 | 2004 | 17 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2004 | 6 | 0.060 |
Why?
|
| Hematocrit | 1 | 2004 | 23 | 0.060 |
Why?
|
| Substance P | 2 | 2019 | 22 | 0.060 |
Why?
|
| Spinal Cord Compression | 1 | 2004 | 8 | 0.060 |
Why?
|
| Peptides | 1 | 2005 | 118 | 0.060 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2004 | 9 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 82 | 0.060 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2004 | 4 | 0.060 |
Why?
|
| North Carolina | 1 | 2008 | 1424 | 0.060 |
Why?
|
| Narcotics | 1 | 2004 | 18 | 0.060 |
Why?
|
| Cystatin C | 1 | 2004 | 28 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2004 | 23 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2006 | 514 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2015 | 143 | 0.060 |
Why?
|
| Hyperesthesia | 1 | 2003 | 1 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 45 | 0.060 |
Why?
|
| Oxyhemoglobins | 1 | 2003 | 6 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 150 | 0.060 |
Why?
|
| Aziridines | 1 | 2003 | 3 | 0.060 |
Why?
|
| Succinate Dehydrogenase | 1 | 2003 | 3 | 0.060 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2003 | 6 | 0.060 |
Why?
|
| Individuality | 1 | 2003 | 5 | 0.060 |
Why?
|
| Elapidae | 1 | 2003 | 2 | 0.060 |
Why?
|
| Elapid Venoms | 1 | 2003 | 2 | 0.060 |
Why?
|
| Nausea | 1 | 2003 | 49 | 0.060 |
Why?
|
| Organophosphorus Compounds | 2 | 2014 | 35 | 0.060 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2003 | 22 | 0.060 |
Why?
|
| Perfusion | 1 | 2003 | 64 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 104 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 9 | 0.060 |
Why?
|
| Aminophylline | 1 | 2002 | 7 | 0.060 |
Why?
|
| Presynaptic Terminals | 1 | 2003 | 36 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2002 | 62 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2003 | 114 | 0.050 |
Why?
|
| Estradiol | 1 | 2003 | 118 | 0.050 |
Why?
|
| Desipramine | 1 | 2002 | 5 | 0.050 |
Why?
|
| Piroxicam | 1 | 2002 | 1 | 0.050 |
Why?
|
| Receptors, Glutamate | 1 | 2002 | 6 | 0.050 |
Why?
|
| Azetidines | 1 | 2002 | 8 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 73 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 93 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2003 | 281 | 0.050 |
Why?
|
| Ectodysplasins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2002 | 130 | 0.050 |
Why?
|
| Pyridines | 1 | 2002 | 78 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 290 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 208 | 0.050 |
Why?
|
| Radioligand Assay | 1 | 2002 | 23 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2003 | 113 | 0.050 |
Why?
|
| Leg | 1 | 2002 | 56 | 0.050 |
Why?
|
| Nicotinic Antagonists | 2 | 2013 | 19 | 0.050 |
Why?
|
| Mice | 2 | 2007 | 2372 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 223 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 51 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 273 | 0.040 |
Why?
|
| Psychology | 1 | 2018 | 22 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2020 | 347 | 0.040 |
Why?
|
| Parasympathomimetics | 1 | 2017 | 3 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 425 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 1219 | 0.040 |
Why?
|
| CREB-Binding Protein | 1 | 2016 | 4 | 0.040 |
Why?
|
| Child | 1 | 2003 | 2221 | 0.040 |
Why?
|
| Psychophysics | 1 | 2016 | 13 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 82 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 73 | 0.030 |
Why?
|
| Proton Pumps | 1 | 2014 | 7 | 0.030 |
Why?
|
| Neurofilament Proteins | 1 | 2014 | 11 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2014 | 52 | 0.030 |
Why?
|
| Dependovirus | 1 | 2014 | 17 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 71 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 9 | 0.030 |
Why?
|
| Receptors, GABA-B | 1 | 2014 | 13 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 343 | 0.030 |
Why?
|
| GABA Agents | 1 | 2013 | 2 | 0.030 |
Why?
|
| Parasympatholytics | 1 | 2013 | 3 | 0.030 |
Why?
|
| Bicuculline | 1 | 2013 | 10 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2013 | 13 | 0.030 |
Why?
|
| Glutamate Decarboxylase | 1 | 2012 | 17 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2012 | 25 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 39 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 37 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2011 | 16 | 0.030 |
Why?
|
| International Cooperation | 1 | 2012 | 25 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2011 | 34 | 0.030 |
Why?
|
| Sodium | 1 | 2011 | 37 | 0.030 |
Why?
|
| Biological Transport | 1 | 2011 | 62 | 0.030 |
Why?
|
| Ligands | 1 | 2011 | 81 | 0.030 |
Why?
|
| Kainic Acid | 1 | 2011 | 6 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2011 | 19 | 0.030 |
Why?
|
| Immunization | 1 | 2011 | 28 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 30 | 0.030 |
Why?
|
| Foot | 1 | 2011 | 40 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2010 | 6 | 0.020 |
Why?
|
| Hair | 1 | 2010 | 28 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 12 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2010 | 19 | 0.020 |
Why?
|
| Nervous System | 1 | 2010 | 15 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 729 | 0.020 |
Why?
|
| Aconitine | 1 | 2009 | 5 | 0.020 |
Why?
|
| Edema | 1 | 2009 | 30 | 0.020 |
Why?
|
| Writing | 1 | 2008 | 11 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 45 | 0.020 |
Why?
|
| Documentation | 1 | 2008 | 32 | 0.020 |
Why?
|
| Point Mutation | 1 | 2007 | 23 | 0.020 |
Why?
|
| Sulfur Isotopes | 1 | 2006 | 2 | 0.020 |
Why?
|
| Theophylline | 1 | 2006 | 4 | 0.020 |
Why?
|
| Citrates | 1 | 2006 | 5 | 0.020 |
Why?
|
| Yohimbine | 1 | 2005 | 4 | 0.020 |
Why?
|
| Guanosine Triphosphate | 1 | 2005 | 8 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2004 | 10 | 0.020 |
Why?
|
| Rectum | 1 | 2004 | 15 | 0.020 |
Why?
|
| Hip Fractures | 1 | 2004 | 30 | 0.020 |
Why?
|
| Patient Care Management | 1 | 2004 | 17 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2004 | 36 | 0.020 |
Why?
|
| Colon | 1 | 2004 | 56 | 0.010 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 92 | 0.010 |
Why?
|
| Algorithms | 1 | 2004 | 463 | 0.010 |
Why?
|